[go: up one dir, main page]

ME02763B - Derivati bipirazola kao inhibitori jak - Google Patents

Derivati bipirazola kao inhibitori jak

Info

Publication number
ME02763B
ME02763B MEP-2017-116A MEP2017116A ME02763B ME 02763 B ME02763 B ME 02763B ME P2017116 A MEP2017116 A ME P2017116A ME 02763 B ME02763 B ME 02763B
Authority
ME
Montenegro
Prior art keywords
jak inhibitors
bipyrazole derivatives
bipyrazole
derivatives
jak
Prior art date
Application number
MEP-2017-116A
Other languages
German (de)
English (en)
French (fr)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song Mei
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang Jia
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ME02763B publication Critical patent/ME02763B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MEP-2017-116A 2013-05-17 2014-05-16 Derivati bipirazola kao inhibitori jak ME02763B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
PCT/US2014/038388 WO2014186706A1 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors
EP14732705.0A EP2997023B9 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors

Publications (1)

Publication Number Publication Date
ME02763B true ME02763B (me) 2018-01-20

Family

ID=50983151

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2017-116A ME02763B (me) 2013-05-17 2014-05-16 Derivati bipirazola kao inhibitori jak
MEP-2019-79A ME03355B (me) 2013-05-17 2014-05-16 Soli bipirazola kao inhibitori jak

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2019-79A ME03355B (me) 2013-05-17 2014-05-16 Soli bipirazola kao inhibitori jak

Country Status (36)

Country Link
US (7) US9382231B2 (me)
EP (5) EP3786162B1 (me)
JP (5) JP6415543B2 (me)
KR (4) KR102442747B1 (me)
CN (2) CN107698569B (me)
AR (2) AR096330A1 (me)
AU (5) AU2014265279B2 (me)
BR (1) BR112015028501B8 (me)
CA (1) CA2911536C (me)
CL (1) CL2015003355A1 (me)
CR (2) CR20190156A (me)
CY (3) CY1119105T1 (me)
DK (3) DK3786162T3 (me)
EA (2) EA036448B1 (me)
ES (4) ES2960731T3 (me)
FI (1) FI3786162T3 (me)
HK (2) HK1221466A1 (me)
HR (4) HRP20231048T1 (me)
HU (4) HUE063817T2 (me)
IL (4) IL242453B (me)
LT (4) LT3786162T (me)
ME (2) ME02763B (me)
MX (2) MX2015015738A (me)
MY (1) MY174788A (me)
PE (2) PE20160126A1 (me)
PH (2) PH12015502563B1 (me)
PL (4) PL3231801T3 (me)
PT (4) PT3786162T (me)
RS (4) RS56012B1 (me)
SG (2) SG10201709469SA (me)
SI (4) SI3786162T1 (me)
SM (4) SMT202100040T1 (me)
TR (1) TR201905814T4 (me)
TW (4) TW202432140A (me)
UA (1) UA117830C2 (me)
WO (1) WO2014186706A1 (me)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2426129T (lt) 2005-12-13 2017-02-10 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
RS54878B1 (sr) 2007-06-13 2016-10-31 Incyte Holdings Corp Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
SI2574168T1 (sl) 2010-05-21 2016-07-29 Incyte Holdings Corporation Topična formulacija zaviralca jak
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
RS55737B1 (sr) 2011-09-02 2017-07-31 Incyte Holdings Corp Heterociklilamini kao inhibitori pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
JP2015537030A (ja) 2012-11-15 2015-12-24 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ルキソリチニブの徐放性投薬形態
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
EA036448B1 (ru) 2013-05-17 2020-11-11 Инсайт Корпорейшн Производные бипиразола в качестве ингибиторов jak
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
PL3110409T3 (pl) * 2014-02-28 2018-12-31 Incyte Corporation Inhibitory jak1 do leczenia zespołów mielodysplastycznych
CN111494386A (zh) 2014-04-08 2020-08-07 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MD3831833T2 (ro) 2015-02-27 2023-04-30 Incyte Holdings Corp Procedee pentru prepararea unui inhibitor PI3K
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
HRP20220599T1 (hr) 2015-11-06 2022-06-24 Incyte Corporation Heterociklički spojevi kao inhibitori pi3k-gama
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
CN109890817B (zh) * 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
AR114810A1 (es) 2018-01-30 2020-10-21 Incyte Corp Procesos e intermedios para elaborar un inhibidor de jak
IL276725B2 (en) * 2018-02-16 2024-09-01 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders
CN113768934A (zh) * 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
MA53561A (fr) 2018-09-05 2022-05-11 Incyte Corp Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
JP7431845B2 (ja) 2018-10-31 2024-02-15 インサイト・コーポレイション 血液疾患の治療のための併用療法
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
JP2022524997A (ja) 2019-03-05 2022-05-11 インサイト・コーポレイション 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
JP2022526301A (ja) 2019-03-19 2022-05-24 インサイト・コーポレイション 尋常性白斑のバイオマーカー
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210471A (zh) 2020-06-02 2022-03-16 美商英塞特公司 製備ｊａｋ１抑制劑之方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11897889B2 (en) 2020-08-18 2024-02-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
EP4200300A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak inhibitor
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
MX2023006638A (es) 2020-12-04 2023-08-22 Incyte Corp Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel.
MX2023006542A (es) 2020-12-08 2023-08-25 Incyte Corp Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
CN114099514A (zh) * 2020-12-29 2022-03-01 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
JP2024516302A (ja) 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹を治療するためのｊａｋ１経路阻害薬
WO2023288197A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
AU2023320077A1 (en) 2022-08-05 2025-02-13 Incyte Corporation Treatment of urticaria using jak inhibitors
WO2024192350A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
HU230798B1 (hu) 2001-10-30 2018-06-28 Novartis Ag Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
LT2426129T (lt) 2005-12-13 2017-02-10 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
RS54878B1 (sr) 2007-06-13 2016-10-31 Incyte Holdings Corp Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US8309718B2 (en) * 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
JP5275371B2 (ja) 2008-03-11 2013-08-28 インサイト・コーポレイション Ｊａｋ阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010135650A1 (en) * 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101805936B1 (ko) 2009-10-09 2017-12-07 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
JP5858434B2 (ja) 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
NZ603446A (en) * 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
SI2574168T1 (sl) 2010-05-21 2016-07-29 Incyte Holdings Corporation Topična formulacija zaviralca jak
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2649061B1 (en) * 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
SG192910A1 (en) 2011-02-24 2013-09-30 Massachusetts Inst Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6014149B2 (ja) 2011-09-22 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール
AR091079A1 (es) * 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
JP2015537030A (ja) 2012-11-15 2015-12-24 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ルキソリチニブの徐放性投薬形態
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
EA036448B1 (ru) 2013-05-17 2020-11-11 Инсайт Корпорейшн Производные бипиразола в качестве ингибиторов jak
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CA2911214A1 (en) 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
PL3110409T3 (pl) 2014-02-28 2018-12-31 Incyte Corporation Inhibitory jak1 do leczenia zespołów mielodysplastycznych
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
ME03546B (me) 2014-12-16 2020-07-20 Novartis Ag Jedinjenja izoksazol hidroksamske kiseline kао inhibiтori lpxc
TW202210471A (zh) 2020-06-02 2022-03-16 美商英塞特公司 製備ｊａｋ１抑制劑之方法
MX2023006638A (es) 2020-12-04 2023-08-22 Incyte Corp Inhibidor de la cinasa janus (jak) con un análogo de la vitamina d para el tratamiento de enfermedades de la piel.

Also Published As

Publication number Publication date
HRP20190713T1 (hr) 2019-06-14
SMT201900223T1 (it) 2019-07-11
EA201592199A1 (ru) 2016-05-31
ME03355B (me) 2019-10-20
SI2997023T1 (sl) 2017-07-31
EP3527263B1 (en) 2020-10-28
PT3786162T (pt) 2023-10-20
BR112015028501A2 (pt) 2017-07-25
TW202432140A (zh) 2024-08-16
AU2021202685B2 (en) 2022-11-17
DK3231801T3 (en) 2019-04-15
SI3527263T1 (sl) 2021-05-31
SG11201509180WA (en) 2015-12-30
US11001571B2 (en) 2021-05-11
US20140343030A1 (en) 2014-11-20
PT3527263T (pt) 2021-02-01
PT2997023T (pt) 2017-05-31
KR20240063187A (ko) 2024-05-10
PL2997023T3 (pl) 2017-08-31
SMT202100040T1 (it) 2021-03-15
SG10201709469SA (en) 2017-12-28
BR112015028501B1 (pt) 2022-11-01
EP2997023B9 (en) 2018-06-13
US10435392B2 (en) 2019-10-08
PH12015502563A1 (en) 2016-02-22
US20180312492A1 (en) 2018-11-01
AU2020202000B2 (en) 2021-03-11
IL282644B (en) 2021-10-31
EP4275756A2 (en) 2023-11-15
MY174788A (en) 2020-05-14
CY1119105T1 (el) 2018-02-14
PT3231801T (pt) 2019-05-24
JP7126741B2 (ja) 2022-08-29
US20160289215A1 (en) 2016-10-06
EA202090291A2 (ru) 2020-05-31
SI3231801T1 (sl) 2019-05-31
AU2020202000A1 (en) 2020-04-09
AU2014265279B2 (en) 2018-09-27
IL242453B (en) 2019-11-28
LT3527263T (lt) 2021-05-10
US20240150327A1 (en) 2024-05-09
EP2997023A1 (en) 2016-03-23
US11905275B2 (en) 2024-02-20
TW201512191A (zh) 2015-04-01
AU2021202685A1 (en) 2021-05-27
AU2018223058B2 (en) 2020-01-02
NZ753638A (en) 2020-11-27
EP4275756A3 (en) 2024-02-07
US20210238168A1 (en) 2021-08-05
TW202116320A (zh) 2021-05-01
RS61482B1 (sr) 2021-03-31
ES2720073T3 (es) 2019-07-17
CN105452239B (zh) 2017-11-21
RS64591B1 (sr) 2023-10-31
EP3786162B1 (en) 2023-08-09
AU2018223058A1 (en) 2018-09-20
CR20150633A (es) 2016-04-05
CN107698569B (zh) 2020-11-27
HUE053122T2 (hu) 2021-06-28
DK3786162T3 (da) 2023-10-09
EP3231801B1 (en) 2019-02-13
ES2626793T3 (es) 2017-07-26
PE20200527A1 (es) 2020-03-09
KR20220127371A (ko) 2022-09-19
CN105452239A (zh) 2016-03-30
US9926301B2 (en) 2018-03-27
CN107698569A (zh) 2018-02-16
JP2016519147A (ja) 2016-06-30
PH12015502563B1 (en) 2019-04-26
TWI719401B (zh) 2021-02-21
EA036448B1 (ru) 2020-11-11
EA202090291A3 (ru) 2020-06-30
IL287313B (en) 2022-03-01
HK1221466A1 (zh) 2017-06-02
CL2015003355A1 (es) 2016-05-27
AU2022263454B2 (en) 2024-01-18
IL282644A (en) 2021-06-30
CA2911536C (en) 2021-07-20
JP6415543B2 (ja) 2018-10-31
LT2997023T (lt) 2017-06-26
UA117830C2 (uk) 2018-10-10
US20230159501A1 (en) 2023-05-25
PL3786162T3 (pl) 2024-04-08
ES2960731T3 (es) 2024-03-06
SMT201700258T1 (it) 2017-07-18
JP2019011364A (ja) 2019-01-24
CR20190156A (es) 2019-05-16
NZ753637A (en) 2020-11-27
MX2020004506A (es) 2021-08-09
HUE063817T2 (hu) 2024-01-28
NZ753639A (en) 2020-11-27
EP3231801A1 (en) 2017-10-18
AR118120A2 (es) 2021-09-22
AU2022263454A1 (en) 2022-12-08
HRP20210119T1 (hr) 2021-03-05
US11591318B2 (en) 2023-02-28
MX2015015738A (es) 2016-03-16
ES2845210T3 (es) 2021-07-26
AU2014265279A1 (en) 2015-11-26
JP2021008493A (ja) 2021-01-28
EP3527263A1 (en) 2019-08-21
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
KR102663357B1 (ko) 2024-05-14
HRP20170795T1 (hr) 2017-08-25
TWI840646B (zh) 2024-05-01
CY1121763T1 (el) 2020-07-31
IL264409A (en) 2019-02-28
CY1123756T1 (el) 2022-05-27
LT3231801T (lt) 2019-08-12
TW201940479A (zh) 2019-10-16
HUE033587T2 (hu) 2017-12-28
IL287313A (en) 2021-12-01
FI3786162T3 (fi) 2023-10-02
SMT202300352T1 (it) 2024-01-10
JP6775560B2 (ja) 2020-10-28
DK3527263T3 (da) 2021-01-25
US9382231B2 (en) 2016-07-05
BR112015028501B8 (pt) 2023-01-24
NZ713999A (en) 2020-11-27
RS56012B1 (sr) 2017-09-29
HK1245769B (zh) 2020-02-07
AR096330A1 (es) 2015-12-23
PL3527263T3 (pl) 2021-05-17
SI3786162T1 (sl) 2024-02-29
PE20160126A1 (es) 2016-02-24
JP2024105557A (ja) 2024-08-06
NZ753636A (en) 2020-11-27
RS58743B1 (sr) 2019-06-28
KR102341908B1 (ko) 2021-12-23
TWI664176B (zh) 2019-07-01
US20200010456A1 (en) 2020-01-09
EA039660B1 (ru) 2022-02-24
EP3786162A1 (en) 2021-03-03
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
IL264409B (en) 2021-05-31
KR102442747B1 (ko) 2022-09-14
HRP20231048T1 (hr) 2023-12-22
CA2911536A1 (en) 2014-11-20
KR20210120120A (ko) 2021-10-06
KR20160019905A (ko) 2016-02-22
WO2014186706A1 (en) 2014-11-20
KR102729910B1 (ko) 2024-11-15
JP2022163162A (ja) 2022-10-25
TR201905814T4 (tr) 2019-05-21
PH12018502125A1 (en) 2019-03-25

Similar Documents

Publication Publication Date Title
HK1221466A1 (zh) 作為 抑制劑的聯吡唑衍生物
HK1215795A1 (zh) 鵝膏毒素衍生物
LT2953944T (lt) Piridazinono amidų dariniai
HK1216531A1 (zh) 新的抑制劑
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
HUE037606T2 (hu) Imidazopirazinon-származékok
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
HK1213566A1 (zh) 新的四唑酮衍生物